Company profile
IMMUNITYBIO, INC.
NASDAQ:IBRXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (9)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ANKTIVA | approved | $50.7MQ2 2026 | 48 | approved |
| ALDOXORUBICIN | phase3 | — | 9 | completed, withdrawn |
| ETBX-011 | phase2 | — | 17 | terminated, withdrawn |
| ETBX-021 | phase2 | — | 9 | terminated, withdrawn |
| ETBX-051 | phase2 | — | 17 | terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (80)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06022224 | phase2_3 | terminated | 2020-12-09 | 2022-06-23 | ImmunityBio, Inc. | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL |
| NCT06710288 | phase2 | recruiting | 2024-11-06 | 2027-05-01 | ImmunityBio, Inc. | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
| NCT07556757 | phase1 | terminated | 2025-04-11 | 2026-07-01 | ImmunityBio, Inc. | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia |
| NCT02138734 | phase1_2 | active_not_recruiting | 2014-07-21 | 2026-09-30 | ImmunityBio, Inc. | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
| NCT04927884 | phase1_2 | terminated | 2021-09-08 | 2022-09-13 | ImmunityBio, Inc. | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761336 | 2024-04-22 | BLA | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SUBSIDIARY OF IMMUNITYBIO, INC. | |||||
Loading… | ||||||||